Marie Skłodowska-Curie Action
Innovative Training Networks (ITN)

2015-2019

 

Funded by

marie curie actions   Marie Curie Actions

 

 

unnamed   
EU Horizon 2020

 

 

european union logo   European Union

 

Argen-X

argen-x

 

Webpage: www.argen-x.com

 

General description

arGEN-X is a publically traded therapeutic antibody biotechnology company. We have a proprietary SIMPLE AntibodyTM discovery platform that allows us to discover high affinity, high diversity antibody sets covering essentially all epitopes of a given target. arGEN-X combines active immunisation of llamas with Fab phage display to induce and harvest conventional antibody output of the immune response. In addition to the antibody discovery platform arGEN-X has three Fc modulation technologies: PK enhancement through NHance; Abdeg technology for driving autoimmune antibodies into destruction and finally arGEN-X has a licence for the PotelligentTM technology which can significantly enhance antibody dependent cytotoxicity and tumour cell killing activity.

 

Key research facilities, infrastructures and equipment

760m2 lab space, equipped with two BiaCore 3000 instruments, FACS machine, AKTA Purifier Llama immunisations are performed off-site under supervision of arGEN-X employees or consultants.

Lijndik